SI1965823T1 - Postopki za dajanje hipoglikemičnih sredstev - Google Patents

Postopki za dajanje hipoglikemičnih sredstev

Info

Publication number
SI1965823T1
SI1965823T1 SI200632086A SI200632086A SI1965823T1 SI 1965823 T1 SI1965823 T1 SI 1965823T1 SI 200632086 A SI200632086 A SI 200632086A SI 200632086 A SI200632086 A SI 200632086A SI 1965823 T1 SI1965823 T1 SI 1965823T1
Authority
SI
Slovenia
Prior art keywords
methods
hypoglycemic agents
administering
administering hypoglycemic
agents
Prior art date
Application number
SI200632086A
Other languages
English (en)
Inventor
Mark A. Bush
Mary Colleen O'neill
Original Assignee
Glaxosmithkline Llc Corporation Service Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1965823(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc Corporation Service Company filed Critical Glaxosmithkline Llc Corporation Service Company
Publication of SI1965823T1 publication Critical patent/SI1965823T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
SI200632086A 2005-11-04 2006-11-03 Postopki za dajanje hipoglikemičnih sredstev SI1965823T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73392005P 2005-11-04 2005-11-04
US74260005P 2005-12-06 2005-12-06
PCT/US2006/060508 WO2007056681A2 (en) 2005-11-04 2006-11-03 Methods for administering hypoglycemic agents
EP06839697.7A EP1965823B1 (en) 2005-11-04 2006-11-03 Methods for administering hypoglycemic agents

Publications (1)

Publication Number Publication Date
SI1965823T1 true SI1965823T1 (sl) 2016-09-30

Family

ID=38024051

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632086A SI1965823T1 (sl) 2005-11-04 2006-11-03 Postopki za dajanje hipoglikemičnih sredstev

Country Status (13)

Country Link
US (4) US8202837B2 (sl)
EP (2) EP1965823B1 (sl)
JP (2) JP2009514900A (sl)
CY (1) CY1118007T1 (sl)
DK (1) DK1965823T3 (sl)
ES (1) ES2586236T3 (sl)
HR (1) HRP20160866T1 (sl)
HU (2) HUE029798T2 (sl)
LT (2) LT1965823T (sl)
PL (1) PL1965823T3 (sl)
PT (1) PT1965823T (sl)
SI (1) SI1965823T1 (sl)
WO (1) WO2007056681A2 (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335608D1 (de) 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2586236T3 (es) 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedimientos para administrar agentes hipoglucémicos
KR101872061B1 (ko) 2005-12-19 2018-06-27 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이 조성물의 제조 방법 및 그 조성물의 이용 방법
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
TWI430806B (zh) * 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP2010530962A (ja) * 2007-06-12 2010-09-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 血漿においてタンパク質を検出する方法
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
PL2373681T3 (pl) * 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
SI2462246T1 (sl) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Hitro vzpostavljanje in/ali prenehanje v bistvu nespremenjenega dovajanja zdravila
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
ES2791690T3 (es) * 2011-02-09 2020-11-05 Glaxosmithkline Llc Formulaciones liofilizadas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2014138371A1 (en) * 2013-03-06 2014-09-12 Glaxosmithkline Llc Host cells and methods of use
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
DK2976325T3 (en) 2013-03-21 2017-06-06 Sanofi Aventis Deutschland SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
CN117241821B (zh) * 2022-03-25 2024-04-09 北京质肽生物医药科技有限公司 多肽缀合物的药物组合物及其使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313439A (en) 1980-03-24 1982-02-02 Biotek, Inc. Automated, spring-powered medicament infusion system
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK134691D0 (da) 1991-07-12 1991-07-12 Novo Nordisk As Apparat
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US6629963B2 (en) * 1996-06-20 2003-10-07 Becton, Dickinson And Company Syringe and needle shield assembly and method of sterilizing such assembly
US6146361A (en) * 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
HUP0103369A3 (en) * 1998-08-28 2002-03-28 Lilly Co Eli Use of insulinotropic peptides
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
US6569143B2 (en) * 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6776776B2 (en) * 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
MXPA03005135A (es) * 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US7235063B2 (en) * 2001-08-21 2007-06-26 D'antonio Consultants International, Inc. Hypodermic injection system
BR0212080A (pt) * 2001-08-23 2006-04-04 Lilly Co Eli composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
EP1585959A4 (en) * 2002-01-08 2007-11-14 Lilly Co Eli PEPTIDE-1 ANALOGUES OF EXTENSION GLUCAGON TYPE
MY139059A (en) 2002-06-24 2009-08-28 Alza Corp Reusable, spring driven autoinjector
WO2004035762A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
CA2510196C (en) 2002-12-20 2014-04-01 Generipharm, Inc. Intracutaneous injection
NZ571243A (en) * 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1592471B1 (en) 2003-02-04 2011-03-23 Novo Nordisk A/S Injection device with rotatable dose setting mechanism
BRPI0411132B8 (pt) 2003-06-12 2021-05-25 Lilly Co Eli protéina de fusão heteróloga e seus usos
BRPI0417684A (pt) * 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
RU2385867C2 (ru) * 2004-05-21 2010-04-10 Новартис Аг Замещенные производные хинолина как ингибиторы митотического кинезина
US7076987B2 (en) * 2004-08-05 2006-07-18 Becton, Dickinson And Company Method of producing tapered or pointed cannula
PT1881850E (pt) 2005-05-13 2010-11-26 Lilly Co Eli Compostos peguilados de glp-1
CN101217940B (zh) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
ES2586236T3 (es) 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedimientos para administrar agentes hipoglucémicos
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法

Also Published As

Publication number Publication date
WO2007056681A2 (en) 2007-05-18
JP2014159431A (ja) 2014-09-04
PL1965823T3 (pl) 2017-08-31
DK1965823T3 (en) 2016-08-22
PT1965823T (pt) 2016-08-18
US20130225489A1 (en) 2013-08-29
WO2007056681A3 (en) 2008-04-10
HRP20160866T1 (hr) 2016-10-07
US20130231282A1 (en) 2013-09-05
EP1965823B1 (en) 2016-05-18
LT1965823T (lt) 2016-10-10
LTPA2016032I1 (lt) 2016-12-12
JP2009514900A (ja) 2009-04-09
US20080254087A1 (en) 2008-10-16
EP1965823A4 (en) 2010-08-04
ES2586236T3 (es) 2016-10-13
HUE029798T2 (en) 2017-03-28
CY1118007T1 (el) 2017-05-17
US8202837B2 (en) 2012-06-19
HUS1600047I1 (hu) 2017-01-30
EP3095456A1 (en) 2016-11-23
EP1965823A2 (en) 2008-09-10
US20160022781A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
HUS1600047I1 (hu) Eljárások hipoglikémiás szerek beadására
IL189212A0 (en) Therapeutic agent for diabetes
EP1962961A4 (en) HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION
HUE054365T2 (hu) Bór-ftalidok terápiás alkalmazásra
GB0506147D0 (en) Therapeutic agents
ZA200706622B (en) Microimplants for ocular administration
IL192369A0 (en) Therapeutic agent for diabetes
GB0519797D0 (en) Therapeutic agents
ZA200901548B (en) Methods for administering long-lasting hypoglycemic agents
GB0505725D0 (en) Therapeutic agents
GB0505437D0 (en) Therapeutic agents
GB0519350D0 (en) Therapeutic agents
GB0518819D0 (en) Therapeutic agents
GB0518817D0 (en) Therapeutic agents
GB0516661D0 (en) Therapeutic agents
GB0514738D0 (en) Therapeutic agents
GB0523998D0 (en) Therapeutic agents
GB0522433D0 (en) Therapeutic agents
ZA200806143B (en) Therapeutic agent for diabetes
GB0502541D0 (en) Medicament
GB0525124D0 (en) Therapeutic agents
GB0513208D0 (en) Therapeutic agents
GB0521538D0 (en) Therapeutic agents
GB0514739D0 (en) Therapeutic agents
GB0514348D0 (en) Therapeutic agents